{name}
{subtitle}
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~25 mi. (Majadahonda, Spain, +383 more cities)
facility
Hospital Universitario Puerta de Hierro - Majadahonda
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer
city
~25 mi. (Majadahonda, Spain, +153 more cities)
facility
Hospital Universitario Puerta de Hierro Majadahonda
condition
Bladder Urothelial Carcinoma, +2 more conditions
drug
BCG solution, +1 more drug
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~25 mi. (Majadahonda, Spain, +140 more cities)
facility
Hospital Universitario Puerta de Hierro ( Site 0596)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH
city
~25 mi. (Majadahonda, Spain, +122 more cities)
facility
Hospital Universitario Clinica Puerta de Hierro
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~25 mi. (Majadahonda, Spain, +199 more cities)
facility
Hospital Universitario Puerta de Hierro ( Site 0678)